Filter Releases
 
News Releases
Date Title and Summary View
Feb 21, 2018
TUSTIN, Calif., Feb. 21, 2018 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a company working to improve patient lives by providing high quality biologics manufacturing services to biotechnology and pharmaceutical companies, today announced that Enzyvant, a subsidiary of Roivant Sciences, has selected Avid as the commer...
Feb 20, 2018
TUSTIN, Calif., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP) today announced the closing of its previously announced underwritten public offering of 10,294,445 shares of its common stock, including 1,294,445 shares sold pursuant to the underwriters' exercise of their option to purchase additional shares.  ...
Feb 15, 2018
TUSTIN, Calif., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP) today announced the pricing of an underwritten public offering of 9,000,000 shares of its common stock at a price to the public of $2.25 per share. The gross proceeds from this offering are expected to be $20,250,000, before deducting underwritin...
Feb 14, 2018
TUSTIN, Calif., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP) today announced that it has commenced an underwritten public offering of its common stock.  Avid Bioservices also intends to grant the underwriter a 30-day option to purchase from it up to an additional 15% of the shares of common stock offered i...
Feb 12, 2018
TUSTIN, Calif. and BOSTON, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP) ("Avid") and Oncologie, Inc. today announced that the companies have entered into an Asset Assignment and Purchase Agreement for Avid's phosphatidylserine (PS)-targeting program including bavituximab. Bavituximab is an investigational ...
Jan 23, 2018
TUSTIN, Calif., Jan. 23, 2018 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a company working to improve patient lives by providing high quality biologics manufacturing services to biotechnology and pharmaceutical companies, today announced that its president and chief executive officer, Roger J. Lias, Ph.D., will deliv...
Jan 5, 2018
TUSTIN, Calif., Jan. 05, 2018 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a company working to improve patient lives by providing high quality biologics manufacturing services to biotechnology and pharmaceutical companies, today announced that it is changing its name to Avid Bioservices, Inc. as part of its t...
= add release to Briefcase

Search Investor Relations